Asset profile
3BNC117
Monoclonal antibody
Evidence outlook · lead readout
NCT03041012 · Hiv
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03041012: The trial randomly assigned 60 participants to four groups, including standard antiretroviral therapy alone and combinations containing 3BNC117, but treatment was not blinded. Its primary outcomes were virologic and reservoir measures rather than hard clinical outcomes, and the registry provides no results showing whether any primary comparison was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2029 (1)
February 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.